Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (DE:GS71)
XETRA:GS71
Holding DE:GS71?
Track your performance easily
GS71 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€15.79 - €21.24
Previous Close€19.55
Volume39.34K
Average Volume (3M)30.57K
Market Cap
€79.25B
Enterprise Value€93.81B
Total Cash (Recent Filing)£5.18B
Total Debt (Recent Filing)£18.02B
Price to Earnings (P/E)16.9
Beta0.13
Next Earnings
Oct 30, 2024EPS Estimate
€0.56Last Dividend Ex-Date
Aug 15, 2024Dividend Yield3.63%
Share Statistics
EPS (TTM)1.16
Shares Outstanding4,145,061,122
10 Day Avg. Volume63,463
30 Day Avg. Volume30,566
Standard Deviation0.07
R-Squared0.04
Alpha0.00397
Financial Highlights & Ratios
Price to Book (P/B)5.63
Price to Sales (P/S)2.18
Price to Cash Flow (P/CF)16.60
P/FCF Ratio25.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.53Price Target Upside4.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
GlaxoSmithKline News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsGSK announced its Nucala COPD PIII trial (MATINEE) has met its primary endpoint, with a clinically meaningful and statistically significant reduction in exacerbations vs placebo in patients with baseline eosinophils >300 cells/uL.
Market ExpansionJemperli expansion opportunities into various cancer treatments, potentially tripling the addressable patient pool.
OncologyOncology assets Ojjaara and Jemperli 50% and 14% above cons respectively driven by strong rollout/new indications.
Bears Say
LitigationThe Delaware Supreme Court has accepted GSK’s request for appeal of the Delaware District court Daubert ruling that saw approximately 73k Zantac claims progress to trial, causing a sharp correction in GSK shares.
Market CompetitionThere are concerns about competitive threats and uncertain repeat dosing schedule for Arexvy, which could impact future sales.
Product ApprovalSurprisingly, ACIP voted against use in patients aged 50-59y, where GSK recently received FDA approval.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.28% Insiders
11.89% Mutual Funds
10.79% Other Institutional Investors
76.04% Public Companies and
Individual Investors
GS71 FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest stock price was €15.79 and its highest was €21.24 in the past 12 months.
What is GlaxoSmithKline’s market cap?
Currently, no data Available
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Oct 30, 2024 which is in 46 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Jul 31, 2024. The company reported €0.514 earnings per share for the quarter, beating the consensus estimate of €0.453 by €0.062.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Annually dividend of €0.18 which represents an annual dividend yield of 3.63%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is €0.56.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,145,061,000 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of €0.514 in its last earnings report, beating expectations of €0.453. Following the earnings report the stock price went down -2.05%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in DE:GS71
---
GlaxoSmithKline Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€20.53 (4.99% Upside)
€20.53 (4.99% Upside)
Insider Transactions
Bought Shares
Worth £176.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.99%
12-Months-Change
Fundamentals
Return on Equity
29.80%
Trailing 12-Months
Asset Growth
-2.35%
Trailing 12-Months
Company Description
GlaxoSmithKline
In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.
---
GS71 Stock 12 Month Forecast
Average Price Target
€20.53
▲(4.99% Upside)
Technical Analysis
Best Analysts Covering GS71
1 Year
1 Year Success Rate
26/37 ratings generated profit
1 Year Average Return
+7.84%
reiterated a buy rating 5 days ago
Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 70.27% of your transactions generating a profit, with an average return of +7.84% per trade.
---